Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12345678910111213...5960»
  • ||||||||||  Review, Journal:  Clinically active pituitary tumors (Pubmed Central) -  Jun 13, 2024   
    Therefore, the role of primary care physicians is very important for achieving an early diagnosis. In addition, patients with pituitary adenomas should always be referred to endocrinologists to ensure optimal diagnosis as well as treatment.
  • ||||||||||  Review, Journal:  Investigational drugs for the Treatment of Acromegaly: new agents to transform therapy. (Pubmed Central) -  Jun 7, 2024   
    Current studies are addressing patient's needing for both new molecules and less invasive routes of administration for already existing drugs. It cannot be ruled out that drugs currently used for other disease such as cancers could be considered in the future for the treatment of acromegaly.
  • ||||||||||  cabergoline / Generic mfg.
    Review, Journal:  Medical treatment of functional pituitary adenomas, trials and tribulations. (Pubmed Central) -  Jun 3, 2024   
    An enlarged panel of effective drugs available with increased knowledge of predictive factors for response and/or adverse effects will enhance the possibility to offer a more individualized treatment. This would not only improve disease control and prognosis, but also quality of life.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Journal:  The direct impact of pegvisomant on osteoblast functions and bone development. (Pubmed Central) -  Jun 1, 2024   
    This study provides a first evidence of the impact of PEG on osteoblast functions both in vitro and in vivo. These findings may have clinically relevant implications for the management of skeletal health in subjects with acromegaly.
  • ||||||||||  Journal:  Alteration in gut microbial characteristics of patients with acromegaly. (Pubmed Central) -  Jun 1, 2024   
    These results suggest that the differences between the microbial communities in patients with acromegaly and those in healthy individuals consist primarily of compositional differences independent of abundance. Prospective studies are needed to further explore the clinical implications of gut microbiome dysbiosis in patients with acromegaly.
  • ||||||||||  Journal:  18F-fluoro-ethyl-tyrosine PET co-registered with MRI in patients with persisting acromegaly. (Pubmed Central) -  May 31, 2024   
    These findings suggest that there is no legacy effect regarding higher cardio-metabolic risk in individuals with acromegaly once they receive surgical treatment. In patients with persisting acromegaly without a clear surgical target on MRI, FET-PET/MRICR is a new tracer to provide additional information to aid decision-making by the multidisciplinary pituitary team.
  • ||||||||||  Review, Journal:  The potential link between acromegaly and risk of acute ischemic stroke in patients with pituitary adenoma: a new perspective. (Pubmed Central) -  May 30, 2024   
    Moreover, activated signaling pathways, including activator of transcription 3 (STAT3), nuclear factor kappa B (NF-?B), nod-like receptor pyrin 3 (NLRP3) inflammasome, and mitogen-activated protein kinase (MAPK) in acromegaly may induce systemic inflammation with the development of cardiovascular complications mainly AIS. Taken together, acromegaly triggers the development of AIS through local and systemic effects by inducing the formation of a cerebral vessel aneurysm, the release of pro-inflammatory cytokines, the development of oxidative stress, ED, and thrombosis correspondingly.
  • ||||||||||  paltusotine (CRN00808) / Crinetics
    Review, Journal:  Oral Octreotide Capsules and Paltusotine in Management of Acromegaly. (Pubmed Central) -  May 30, 2024   
    Adverse events with both OOC and paltusotine were reflective of those recognized with iSRL and occurred at a similar frequency. OOC and paltusotine are well-received additions to the therapeutic armamentarium in medical therapy for the management of acromegaly; however, further data on efficacy, tumour control and shrinkage are required to allow positioning of this medication within the management algorithm for acromegaly.
  • ||||||||||  Review, Journal:  Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly. (Pubmed Central) -  May 30, 2024   
    The data showed a patient preference to continue in the OOC arm for the extension phase of the trials. From the clinical pharmacological perspective, oral formulation of octreotide has the advantage of efficacy and safety with respect to injectable octreotide.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
    Retrospective data, Journal:  Pegvisomant or pasirotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. (Pubmed Central) -  May 28, 2024   
    From the clinical pharmacological perspective, oral formulation of octreotide has the advantage of efficacy and safety with respect to injectable octreotide. Despite the more aggressive behavior of GH/PRL-Pit-NETs than GH-Pit-NETs, no differences in the rate of IGF-1 control with pegvisomant and pasireotide is observed between both groups, and both drugs are effective treatments to control IGF-1 and PRL hypersecretion in these tumors.
  • ||||||||||  Observational data, Journal:  Acromegaly screening in patients with hyperprolactinemia and pituitary adenoma (Pubmed Central) -  May 26, 2024   
    The disease was detected in 3 cases (3.2%) out of 94 people with hyperprolactinemia and pituitary adenoma without clinical manifestations of acromegaly. We consider the study of IGF-1 levels justified as a screening for acromegaly in patients with hyperprolactinemia and pituitary adenoma.
  • ||||||||||  cabergoline / Generic mfg.
    Journal:  Effectiveness of Combined First-Line Medical Treatment in Acromegaly with Prolactin Co-secretion. (Pubmed Central) -  May 21, 2024   
    Of the modifiable factors of adherence, patient-doctor relationship seemed to play a crucial role and could be one leverage point to improve adherence. In GH&PRL-PA the biochemical control achieved with fgSRL as monotherapy is substantially worse than in patients harboring GH-PA, supporting the inclusion of cabergoline as first line medical treatment in combination with fgSRLs in these subgroups of patients.
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Acromegaly: Balance, Falls and Fracture Risk (clinicaltrials.gov) -  May 15, 2024   
    P=N/A,  N=34, Completed, 
    In GH&PRL-PA the biochemical control achieved with fgSRL as monotherapy is substantially worse than in patients harboring GH-PA, supporting the inclusion of cabergoline as first line medical treatment in combination with fgSRLs in these subgroups of patients. Recruiting --> Completed | N=60 --> 34 | Trial completion date: Mar 2025 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2024
  • ||||||||||  Biomarker, Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker:  Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly. (Pubmed Central) -  May 15, 2024   
    PD-L1 expression and CD8?+?T cell infiltration, either independently or combined with SSTR2 expression and T2WI-MRI intensity, could form a predictive model guiding clinical decisions on fg-SRL employment. Furthermore, targeting PD-L1 through immunotherapy and embracing second-generations of SRL with higher affinity to SSTR5 represent promising strategies to tackle fg-SRL resistance in somatotropinomas.
  • ||||||||||  Journal, HEOR:  Orofacial traits related to oral health-related quality of life in Brazilian acromegaly patients. (Pubmed Central) -  May 13, 2024   
    Furthermore, targeting PD-L1 through immunotherapy and embracing second-generations of SRL with higher affinity to SSTR5 represent promising strategies to tackle fg-SRL resistance in somatotropinomas. The findings suggest that smoking, arthrosis and orofacial alterations (mandibular protrusion, open bite, crossbite and diastema) have a negative impact on oral health-related quality of life in acromegaly patients.
  • ||||||||||  Review, Journal:  The molecular biology of sporadic acromegaly. (Pubmed Central) -  May 9, 2024   
    Specific somatic mutations in GNAS, PTTG1, GIPR, HGMA2, MAST and somatic variants associated with cAMP, calcium signaling, and ATP pathways have also been associated with the development of acromegaly. This review focuses on the oncogenic mechanisms by which sporadic acromegaly can develop, covering a complex series of molecular alterations that ultimately alter the balance between proliferation and apoptosis, and dysregulated hormonal secretion.
  • ||||||||||  Review, Journal:  Histopathology of growth hormone-secreting pituitary tumors: State of the art and new perspectives. (Pubmed Central) -  May 9, 2024   
    Therefore, the integration of biochemical, clinical, radiological, and histopathological elements is fundamental for proper diagnosis and management of pituitary adenomas/PitNETs, to be performed in referral Centers. In more recent times, the importance of genetic and epigenetic evaluation in the characterization of pituitary tumors (i.e., early identification of aggressive variants) has been outlined by some large studies, with the intention of improving targeted treatments.
  • ||||||||||  Review, Journal:  Genetic diagnosis in acromegaly and gigantism: From research to clinical practice. (Pubmed Central) -  May 9, 2024   
    Even more, genetic testing and clinical screening of at-risk individuals have a positive impact on disease outcomes, by allowing for the timely detection and treatment of somatotrophinomas at early stages. Future research should focus on determining the actual frequency of novel genetic drivers of somatotrophinomas in the general population, developing up-to-date disease-specific multi-gene panels for clinical use, and finding strategies to improve access to modern genetic testing worldwide.
  • ||||||||||  Review, Journal:  "Micromegaly": Acromegaly with apparently normal GH, an entity on its own? (Pubmed Central) -  May 9, 2024   
    Even though, the frequency and severity of clinical signs and comorbidities are similar to those of patients with classic acromegaly. In conclusion, micromegaly seems to be a distinct clinical entity with a different biological behavior characterized by a low GH output.
  • ||||||||||  Resolving the Mystery of Corticotropinoma using Radiolabeled V1b Receptor Antagonist (714B (Convention Center); In-Person) -  May 8, 2024 - Abstract #SNMMI2024SNMMI_2248;    
    [68Ga]Ga-modified vasopressin showed no uptake in normal pituitary and acromegaly patients. A good uptake in corticotropinoma cases suggests the promising potential of [68Ga]Ga- modified vasopressin in the localization of corticotropinoma.
  • ||||||||||  Trial completion date, Trial primary completion date:  Treatment Patterns and Treatment Outcomes for Acromegaly (clinicaltrials.gov) -  May 6, 2024   
    P=N/A,  N=520, Active, not recruiting, 
    Cutaneous androgenization findings such as skin tag, seborrhoea, acne Trial completion date: Jul 2023 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2025
  • ||||||||||  Faculty (156ABC - BCEC) -  May 5, 2024 - Abstract #ENDO2024ENDO_3109;    
    Trial completion date: Jul 2023 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2025 The role of radiation therapy in the management of patients with Cushing disease and acromegaly will be discussed using a case-based approach